Article information
Full text is only aviable in PDF
Bibliografía
[1.]
R. Pawels, A. Sonia Buist, P. Calverley, C. Jenkins, S. Hurd.
Global strategy for the diagnosis, management and prevention of chronic obstrtuctive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD). Workshop summay.
Am J Respir Crit Care Med, 163 (2001), pp. 1256-1276
[2.]
N.M. Siafakas, P. Vermeire, N.B. Pride, P. Paoletti, J. Gibson, P. Howard, Force on behalf of the Task, et al.
Optimal assessment and management of chronic obstructive pulmonary disease (COPD).
Eur Respir J, 8 (1995), pp. 1398-1420
[3.]
American Thoracic Society.
Definitions, epidemiology, pathophysiology, diagnosis and staging.
Am J Respir Crit Care Med, 152 (1995), pp. S78-S83
[4.]
C.J.L. Murray, A.D. Lopez.
Mortality by cause for eight regions of the world: global burden of disease study.
Lancet, 349 (1997), pp. 1269-1276
[5.]
N.R. Anthonisen, J.E. Connett, J.P. Kiley, M. Altose, W. Bailey, A. Sonia Buist, et al.
Effect of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study.
Jama, 272 (1994), pp. 1497-1505
[6.]
R. Casaburi, D. Mahler, P. Jones, A. Wanner, G. SanPedro, R. ZuWallack, et al.
A long term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.
Eur Respir J, 19 (2002), pp. 217-224
[7.]
D. Mahler, J. Donohue, R. Barbee, M. Goldman, N. Gross, M. Wisnewiski, et al.
Efficacy of salmeterol xinoafate in the treatment of COPD.
Chest, 115 (1999), pp. 957-965
[8.]
P. Jones, T. Bosh.
Quality of life changes in COPD patients treated with salmeterol.
Am J Respir Crit Care Med, 155 (1997), pp. 1283-1289
[9.]
W. Vincken, J. Van Noord, A. Greefhorst, T. Bantje, S. Kesten, L. Korducki, a.l. et.
on behalf of the Dutch/Belgian tiotropium study group.
Eur Respir J, 19 (2002), pp. 209-216
[10.]
R. ZuWallack, D. Mahler, D. Reilly, N. Church, A. Emmet, K. Rickard, et al.
Salmeterol plus theophylline combination therapy in the treatment of COPD.
Chest, 119 (2001), pp. 1628-1630
[11.]
P.S. Burge, P.M. Calverley, P.W. Jones, S. Spencer, J.A. Anderson, T.K. Maslen.
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
Bmj, 320 (2000), pp. 1297-1303
[12.]
The Lung Health Study Research Group.
Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.
N Engl J Med, 343 (2000), pp. 1902-1909
[13.]
J.G. Hay, P. Stone, J. Carter, S. Church, A. Eyre-Brook, M.G. Pearson, et al.
Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease.
Eur Respir J, 5 (1992), pp. 659-664
[14.]
M. Friedman, C. Serby, S. Menjoge, J. Wilson, D. Hilleman, T. Witek.
Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.
Chest, 115 (1999), pp. 635-641
[15.]
D. O'Donnell, M. Lam, K. Webb.
Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 160 (1999), pp. 542-549
[16.]
S. McMahon, A. Rodgers.
The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives.
Clin Exper Hypertens, 15 (1993), pp. 967-978
[17.]
Blood pressure lowering treatment trialists' collaboration.
Effects of ACE inhibitors, calcium antagonists, and other blood-pressurelowering drugs: results of prospectively designed overviews of randomized trials.
Lancet, 356 (2000), pp. 1955-1964
[18.]
S. Rennard, M. Carrera, A. Agusti.
Management of chronic obstructive pulmonary disease: are we going anywhere?.
Eur Respir J, 16 (2000), pp. 1035-1040
[19.]
Nocturnal Oxygen Therapy Trial Group.
Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease.
Ann Intern Med, 93 (1980), pp. 391-398
[20.]
Medical Research Council Working Party.
Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema.
Lancet, 1 (1981), pp. 681-686
[21.]
N.C. Dean, J.K. Brown, R.B. Himelman, J.J. Doherty, W.M. Gold, M.S. Stulbarg.
Oxygen may improve dyspnea and endurance in patients with chronic obstructive pulmonary disease and only mild hypoxemia.
Am Rev Respir Dis, 146 (1992), pp. 941-945
[22.]
G.J. Criner, B.R. Celli.
Ventilatory muscle recruitment in exercise with O2 in obstructed patients with mild hypoxemia.
J Appl Physiol, 63 (1987), pp. 195-200
[23.]
A. Ries, B. Carlin, V. Carrieri-Kohlman, R. Casaburi, B. Celli, C. Emery, et al.
Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines.
Chest, 112 (1997), pp. 1363-1396
[24.]
T. Griffith, M. Burr, I. Campbell, V. Lewis-Jenkins, Mullins, K. Shiels, et al.
Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised control trial.
Lancet, 355 (2000), pp. 362
[25.]
L. Brochard, J. Mancebo, M. Wysocki, F. Lofaso, G. Conti, A. Rauss, et al.
Noninvasive ventilation for acute exacerbation of chronic obstructive pulmonary disease.
N Engl J Med, 333 (1995), pp. 817-822
[26.]
J. Bott, M.P. Carroll, J.H. Conway, S. Keilty, E. Ward, A. Brown, et al.
Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease.
Lancet, 341 (1993), pp. 1555-1557
[27.]
N. Kramer, T. Meyer, J. Meharg, R. Cece, N.S. Hill.
Randomized prospective trial of non-invasive positive pressure ventilation in acute respiratory failure.
Am J Respir Crit Care Med, 151 (1995), pp. 1799-1806
[28.]
D. Geddes, M. Davis, H. Koyama, D. Hansel, V. Pastorino, J. Pepper, et al.
Effect of lung volume reduction surgery in patients with severe emphysema N Engl J Med, 343 (2000), pp. 239-245
[29.]
M. Decramer, R. Gosselink, T. Troosters, M. Verschueren, G. Evers.
Muscle weakness is related to utilization of health care resources in COPD patients.
Eur Respir J, 10 (1997), pp. 417-423
[30.]
A.J. France, R.J. Prescott, W. Biernacki, A.L. Muir, W. MacNee.
Does right ventricular function predict survival in patients with chronic obstructive lung disease?.
Thorax, 43 (1988), pp. 621-626
[31.]
A.M. Schols, J. Slangen, L. Volovics, E.F. Wouters.
Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 157 (1998), pp. 1791-1797
[32.]
J.E. Hodgkin.
Prognosis in chronic obstructive pulmonary disease.
Clin Chest Med, 11 (1990), pp. 555-569
[33.]
N.R. Anthonisen, E. Wright, J.E. Hodgkin, group the IPPB trial.
Prognosis in chronic obstructive pulmonary disease.
Am Rev Respir Dis, 133 (1986), pp. 14-20
[34.]
Intermittent Positive Pressure Breathing Trial Group.
Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease.
Ann Intern Med, (1983), pp. 612-620
[35.]
D.A. Gerardi, L. Lovett, M.L. Benoit-Connors, J.Z. Reardon, R.L. ZuWallack.
Variables related to increased mortality following outpatient pulmonary rehabilitation.
Eur Respir J, 9 (1996), pp. 431-435
[36.]
C. Landbo, E. Prescott, P. Lange, J. Vestbo, T.P. Almdal.
Prognostic value of nutritional status in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 160 (1999), pp. 1856-1861
[37.]
M. Ferrer, J. Alonso, J. Morera, R. Marrades, A. Khalaf, C. Aguar, et al.
Chronic obstructive pulmonary disease and health related quality of life.
Ann Int Med, 127 (1997), pp. 1072-1079
[38.]
N. Dewan, S. Rafique, B. Kanwar, H. Satpathy, K. Ryschon, G. Tillotson, et al.
acute exacerbation of COPD. Factors associated with poor treatment outcome.
Chest, 117 (2000), pp. 662-671
[39.]
L. Sweet, C.W. Zwillich.
Dyspnea in the patient with chronic obstructive pulmonary disease.
Clin Chest Med, 11 (1990), pp. 417-445
[40.]
D. Mahler, C. Wells.
Evaluation of clinical methods for rating dyspnea.
Chest, 93 (1988), pp. 580-586
[41.]
A. Ries, R. Kaplan, T. Limberg, L. Prewitt.
Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes inpatients with COPD.
Ann Int Med, 122 (1995), pp. 823-832
[42.]
T. Hajiro, K. Nishimura, M. Tsukino, A. Ikeda, H. Koyama, T. Izumi.
Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 157 (1998), pp. 785-790
[43.]
L. Szekely, D. Oelberg, C. Wright, D. Johnson, J. Wain, B. Trotman- Dickenson, et al.
Preoperative predictors of operative mortality in COPD patients undergoing bilateral lung volume reduction surgery.
Chest, 111 (1997), pp. 550-558
[44.]
M. Sha, V. Hasselblad, M. Gheorgiadis, S. Adams, K. Swedberg, R. Califf, et al.
Prognostic usefulness of the 6 minute walk in patients with advanced congestive heart failure secondary to ischemic and non-ischemic cardiomyopathy.
Am J Cardiol, 88 (2001), pp. 987-993
[45.]
S. Miyamoto, N. Nagaya, T. Satoh, S. Kyotani, F. Sakamaki, M. Fujita, et al.
Clinical correlates and prognostic significance of 6 minute walk in patients with pulmonary hypertension. Comparison with cardiopulmonary exercise testing.
Am J Respir Crit Care Med, 161 (2000), pp. 487-492
[46.]
V. Pinto-plata, M. Girish, J. Taylor, B. Celli.
Natural decline in 6 minutes walking distance in COPD.
Am J Respir Crit Care Med, 158 (1998), pp. A20
[47.]
C.G. Cote, B. Celli.
COPD patients the 6 minutes walking distance predicts health care resources utilization better than FEV1, MRC dyspnea scale and arterial blood gases.
Eur Respir J, 14 (1998), pp. A383
Copyright © 2002. Sociedad Española de Neumología y Cirugía Torácica
